Palisade Bio Announces European Patent Office Issued Decision To Grant Notice For Patent Number 4,157,853 Titled "Gut Microbiota Bioactivated PDE4 Inhibitor Precursors."
Portfolio Pulse from Benzinga Newsdesk
Palisade Bio has announced that the European Patent Office has issued a decision to grant a patent for 'Gut Microbiota Bioactivated PDE4 Inhibitor Precursors,' covering their PALI-2108 and PALI-1908 programs. This patent provides Composition of Matter coverage until beyond 2042. PALI-2108 is being developed for Ulcerative Colitis, and PALI-1908 for Crohn's Disease.
July 19, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Palisade Bio has received a European patent for 'Gut Microbiota Bioactivated PDE4 Inhibitor Precursors,' covering their PALI-2108 and PALI-1908 programs. This patent extends their Composition of Matter coverage until beyond 2042, potentially enhancing the company's market position and future revenue streams.
The granting of this patent secures long-term intellectual property protection for Palisade Bio's key drug candidates, PALI-2108 and PALI-1908. This strengthens their competitive position and could lead to increased investor confidence and potential future revenue growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100